Table 2 On-going combination immunotherapy trials in urothelial cancer

Nivolumab +/− Ipilimumab (CheckMate-032)

1150

70

I/II

II

NCT01928394

NCT02553642

December 2018

September 2018

Atezolizumab + MOXR0916 (anti-OX40) +/− Bevacizumab

762

I

NCT02410512

August 2018

CPI-444 + Atezolizumab

534

I/Ib

NCT02655822

June 2018

Pembrolizumab + PLX3397 (CSF1R)

400

I/II

NCT02452424

July 2019

BMS-986106 (anti-LAG3) +/− Nivolumab

360

I/II

NCT01968109

October 2019

MK-7684 +/− Pembrolizumab

336

I

NCT02964013

March 2020

GSK3174998 (anti-OX40) +/− Pembrolizumab

264

I

NCT02528357

January 2020

Pembrolizuamb + Lenvatinib

250

Ib/II

NCT02501096

January 2018

Durvalumab + Epacadostat

185

I/II

NCT02318277

January 2018

Pembrolizumab + Ramucirumab

155

I

NCT02443324

June 2018

Nivolumab + Cabozantinib +/− Ipilimumab

135

I

NCT02496208

December 2017

Atezolizumab + Epacadostat

118

I

NCT02298153

November 2020

Durvalumab + (Olaparib or Vistusertib or

AZD1775 or AZD4547)

110

I

NCT02546661

March 2019

Durvalumab + Tremelimumab + polyICLC (TLR3 agonist)

102

I/II

NCT02643303

August 2022

Pembrolizuamb +/− Acalabrutinib

75

II

NCT02351739

Summer 2017

Tremelimumab +/− Durvalumab

64

II

NCT02527434

October 2018

Ipilimumab + Enoblituzumab (anti-B7-H3)

59

I

NCT02381314

March 2018

Atezolizumab + B-701 (FGFR3 inhibitor)

48

Ib

NCT03123055

April 2017

Pembrolizumab + Vorinostat

42

I

NCT02619253

May 2018

Pembrolizumab + Docetaxel or Gemcitabine

38

I

NCT02437370

December 2019

Nivolumab + Enadenotucirev (oncolytic virus)

30

I

NCT02636036

June 2018

Avelumab + NHS-IL-12

30

I

NCT02994953

April 2018

Pembrolizumab + Paclitaxel

27

II

NCT02581982

March 2019

Nivolumab + IFN-γ

15

I

NCT02614456

December 2017